Squarepoint
LUCD icon

Squarepoint’s Lucid Diagnostics LUCD Stock Holding History

Squarepoint’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-115,022
Closed -$132K – 4732
2026
Q1 		$132K Sell
115,022
-227,861
-66% -$290K ﹤0.01% 4027
2025
Q4 		$374K Buy
342,883
+325,493
+1,872% +$364K ﹤0.01% 3445
2025
Q3 		$17.6K Sell
17,390
-94,845
-85% -$104K ﹤0.01% 4292
2025
Q2 		$129K Buy
112,235
+81,713
+268% +$106K ﹤0.01% 4103
2025
Q1 		$45.5K Buy
+30,522
New +$36.6K ﹤0.01% 4356

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Squarepoint's LUCD Position: Q2 2026 in Review

Squarepoint sold out of Lucid Diagnostics (LUCD) in Q2 2026, closing a stake of 115,022 shares — an estimated $132K sold.

Squarepoint first reported a position in LUCD in Q1 2025 and held it in 5 quarters. The position peaked at $374K in Q4 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Squarepoint reported no remaining Lucid Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 115,022 Lucid Diagnostics shares in Q2 2026, an estimated $132K.
  • Squarepoint first reported a position in Lucid Diagnostics in Q1 2025 and held it in 5 quarters.
  • Squarepoint's Lucid Diagnostics position peaked at $374K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.